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Abstract
Antimalarial drug resistance is a major constraint for malaria control and elimination efforts.
Artemisinin-based combination therapy is now the mainstay for malaria treatment. However,
delayed parasite clearance following treatment with artemisinin derivatives has now spread
in the Greater Mekong Sub region and may emerge or spread to other malaria endemic
regions. This spread is of great concern for malaria control programmes, as no alternatives
to artemisinin-based combination therapies are expected to be available in the near future.
There is a need to strengthen surveillance systems for early detection and response to the
antimalarial drug resistance threat. Current surveillance is mainly done through therapeutic
efficacy studies; however these studies are complex and both time- and resource-intensive.
For multiple common antimalarials, parasite drug resistance has been correlated with
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specific genetic mutations, and the molecular markers associated with antimalarial drug
resistance offer a simple and powerful tool to monitor the emergence and spread of resistant
parasites. Different techniques to analyse molecular markers associated with antimalarial
drug resistance are available, each with advantages and disadvantages. However, proce-
dures are not adequately harmonized to facilitate comparisons between sites. Here we
describe the target product profiles for tests to analyse molecular markers associated with
antimalarial drug resistance, discuss how use of current techniques can be standardised,
and identify the requirements for an ideal product that would allow malaria endemic coun-
tries to provide useful spatial and temporal information on the spread of resistance.
Background
Antimalarial drug resistance is a major concern for malaria control and elimination pro-
grammes. Indeed, Plasmodium falciparum parasites have consistently developed resistance to
the most widely used antimalarials, pushing national malaria control programmes to regular
changes in antimalarial drug policy [1]. Artemisinin-based combination therapy (ACT) is now
the mainstay for malaria treatment in endemic regions, following recommendations from the
World Health Organization (WHO) [2]. However parasites with decreased susceptibility to
artemisinin derivatives have emerged over the last ten years in different parts of the Greater
Mekong Sub region (GMS) [3–7]. ACTs are failing due to both decreased susceptibility to arte-
misinin compounds and resistance to their partner drugs in Southeast Asia [8–14]. Strength-
ening of existing surveillance systems is needed to detect drug resistance in malaria endemic
countries as it emerges or spreads to other regions. Antimalarial drug resistance surveillance is
currently done through three different strategies: in vivo studies such as therapeutic efficacy
studies (TESs), in vitro/ex vivo studies of cultured malaria parasites, and molecular studies
assessing known markers of antimalarial drug resistance. These three techniques are comple-
mentary, but each has advantages and disadvantages [15]. TES remains the gold standard for
informing antimalarial drug policy change, as outcomes have direct clinical relevance [16], but
these studies are challenging to conduct due to heavy financial and logistical constraints [17],
and they cannot always confirm resistance, especially for combination therapies [18]. Indeed,
only monotherapy studies allow for the accurate differentiation of the drug component caus-
ing apparent ACT treatment failure [19]. In vivo/ex vivo studies, such as measurement of IC50
(50% inhibitory concentration of a drug) or ring stage survival assays, can provide useful infor-
mation about parasite susceptibility to antimalarial drugs, but require heavy infrastructure for
parasite culture. Performance of these assays is generally restricted to well-equipped laborato-
ries to validate new molecular markers of antimalarial drug resistance [20], or to link a resis-
tance phenotype to a genotype [21]. Molecular studies of antimalarial drug resistance markers
provide information about the parasite genetics associated with resistance, i.e. single nucleo-
tide polymorphisms (SNPs) or gene copy number variations (CNVs) that are associated with
decreased susceptibility of parasites to antimalarial drugs. After markers of resistance have
been identified by genotype-phenotype discovery studies, detection of these molecular mark-
ers provides a feasible means of tracking emergence and/or spread of antimalarial drug resis-
tance, as easy-to-collect dried blood spot (DBS) samples can be used [22,23]. While numerous
methodologies for blood spot collection, DNA extraction, PCR amplification, and analysis of
molecular markers have been described, standardisation of these approaches is lacking [1].
TPP molecular assays for antimalarial resistance
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Given the potential role of molecular surveillance of drug resistance markers, a standardised
approach is important to allow for comparability across the globe.
Here we describe the target product profile (TPP), with minimal and optimal characteris-
tics, for techniques to analyse molecular markers associated with antimalarial drug resistance.
This TPP was developed by a group of experts from academic institutions, public health insti-
tutions and industry at a meeting convened by the Foundation for Innovative New Diagnostics
(FIND).
Methodology
A draft TPP was developed based on a landscape analysis of antimalarial drug resistance sur-
veillance methods performed by FIND [1]. The listed properties were defined according to
FIND’s standard procedures (https://www.finddx.org/target-product-profiles/), with charac-
teristics described as either “minimal” or “optimal”. The experts were selected based on their
experience and expertise in the field of molecular markers of antimalarial drug resistance. The
participants selection was based on a review previously conducted by FIND on the methods
used for surveillance of antimalarial drug resistance [1]. Identified experts were contacted by
email, invited to participate in the meeting and provided with a brief summary of the meeting’s
objectives (S1 Table). Those who confirmed their attendance were provided with the draft
TPP prior to the meeting including a questionnaire (S2 Table). The meeting was organised by
FIND and held in Geneva on 21 and 22 September 2017 to reach consensus on the TPP. The
experts were asked to present the different molecular techniques that are used in their labora-
tories and discussed their advantages and disadvantages (Table 1).
A session was organised to go through the draft TPP using the pre-established question-
naire as a guideline. Experts were asked to provide their opinion on the different assay charac-
teristics, and discuss about them to reach a consensus. The discussion was moderated by one
of interviewer from FIND. All the final decisions were made by consensus; none of the deci-
sions were taken by voting. Comments and suggestions from the experts were collected and
compiled in the meeting’s report. After the meeting, a revised draft TPP following suggestions
from the experts’ meeting was sent to the meeting participants along with the meeting’s report.
The experts were asked to review the revised draft and the meeting report, and confirm that
both documents accurately reflected the discussions they had during the meeting. They were
asked as well to provide additional suggestions on the revised TPP, and based on those com-
ments, the TPP was finalised and sent to all participants for final review and approval. More
details about the meeting can be found in S3 Table.
Results
Participants
Twenty seven experts (including four observers) were invited to the meeting. Eighteen experts
(including four observers) were able to attend the meeting, whereas nine experts were not
available. All the experts are working in the field of antimalarial drug resistance. The majority
of the participants (n = 13 [72.2%]) were research group leaders from academic institutions;
other participants were coming from public health institutions such as WHO and the Centers
for Disease Control and Prevention (CDC) or industry (Table 2). Most of the participants
were coming from institutions based in the United States of America (USA), the United King-
dom (UK), Switzerland and France, while only 7 of them were female (Table 2).
TPP molecular assays for antimalarial resistance
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Table 1. Laboratory methods to assess molecular markers associated with antimalarial drug resistance.
Assay Required equipment
and reagents
Required
personnel
Assay
duration
(From DNA
extraction to
results)
Cost per
sample
(USD)
Excluding
labour
Positive and
negative
controls
Limitations Appropriate setting
for use
Ref.
Mutation-specific-
PCR
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Reagents
DNA extraction
reagents
PCR reagents
Trained staff < 8h 8–10 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[24–
27]
PCR-RFLP Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Reagents
DNA extraction
reagents
PCR reagents
Restriction enzymes
Trained staff >24h 7–10 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[28,29]
Molecular beacons Equipment
Incubator
Centrifuge
Hood
Thermocycler
Computer
spectrofluorometer
Reagents
DNA extraction
reagents
PCR reagents
Fluorescent
oligonucleotide
probes
Trained staff <8h 9–12 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[30]
Dot blot
hybridization
Equipment
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Dot blot unit
Reagents
DNA extraction
reagents
PCR reagents
Dot blot reagents
Oligonucleotide
probes
Trained staff >24h 9–12 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[31]
(Continued)
TPP molecular assays for antimalarial resistance
PLOS ONE | https://doi.org/10.1371/journal.pone.0204347 September 20, 2018 4 / 18
Table 1. (Continued)
Assay Required equipment
and reagents
Required
personnel
Assay
duration
(From DNA
extraction to
results)
Cost per
sample
(USD)
Excluding
labour
Positive and
negative
controls
Limitations Appropriate setting
for use
Ref.
Primer extension
(Snapshot)
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Sequencer
Reagents
DNA extraction
reagents
PCR reagents
Oligonucleotide
probes
Trained staff >10h 12–15 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[32]
Real time PCR Equipment
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Computer
Reagents
DNA extraction
reagents
PCR reagents
Oligonucleotide
probes
Trained staff <6h 13–20 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- National reference
laboratory
- Research laboratory
[33–
35]
Sanger sequencing Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Sequencer
Reagents
PCR reagents
Sequencing reagents
Highly trained
staff, especially
for data
analysis
>72h 6–40 - Reference
strain
- High initial
investment
- Requires high
volume computing
system for data
analysis
- Regional reference
laboratory
- Research laboratory
[36,37]
SSOP-ELISA Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
ELISA reader
Reagents
DNA extraction
reagents
PCR reagents
Oligonucleotide
probes
ELISA plates
Trained staff <12h 12–14 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[38]
(Continued)
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Table 1. (Continued)
Assay Required equipment
and reagents
Required
personnel
Assay
duration
(From DNA
extraction to
results)
Cost per
sample
(USD)
Excluding
labour
Positive and
negative
controls
Limitations Appropriate setting
for use
Ref.
Microarray Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Fluorescence scanner
Reagents
DNA extraction
reagents
PCR reagents
Fluorescent
oligonucleotide
probes
Microarray spotted
slides
Trained staff <8h 6–8 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- National reference
laboratory
- Research laboratory
[39,40]
Next generation
sequencing
(WGS, amplicon
sequencing)
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Sequencer
Reagents
PCR reagents
Sequencing reagents
Highly trained
staff, especially
for data
analysis
>48h 10–200 - Reference
strain
- Higher coverage
needed to increase
specificity
- Requires high
volume computing
system for data
analysis
- Regional reference
laboratory
- Research laboratory
[41,42]
Ligase detection
reaction fluorescent
microsphere
(LDR-FM)
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Magpix instrument
Reagents
DNA extraction
reagents
PCR reagents
Fluorescent
oligonucleotide
probes
Trained staff <8h 4–6 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- National reference
laboratory
- Research laboratory
[29,43]
(Continued)
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PLOS ONE | https://doi.org/10.1371/journal.pone.0204347 September 20, 2018 6 / 18
Table 1. (Continued)
Assay Required equipment
and reagents
Required
personnel
Assay
duration
(From DNA
extraction to
results)
Cost per
sample
(USD)
Excluding
labour
Positive and
negative
controls
Limitations Appropriate setting
for use
Ref.
Nucleic acid lateral
flow immunoassay
(NALFIA)
Equipment
Incubator
Centrifuge
Hood
Thermocycler
Gel electrophoresis
unit
Gel imaging system
Computer
Reagents
DNA extraction
reagents
PCR reagents
oligonucleotide
probes
Lateral flow test
Trained staff <6h 5–10 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- National reference
laboratory
- Research laboratory
[44]
Loop mediated
isothermal
amplification
(LAMP)
Equipment
Incubator
Centrifuge
Hood
Reagents
DNA extraction
reagents
LAMP reagents
Staff with
minimal
training
<4h 20–120 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput>
- Field laboratory [45,46]
LAMP-lateral flow
dipstick
Equipment
Incubator
Centrifuge
Hood
Reagents
DNA extraction
reagents
LAMP reagents
Lateral flow test
Oligonucleotide
probes
Staff with
minimal
training
<4h 20–120 - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Cannot detect
copy number
variations
- Low throughput
- Field laboratory [45,47]
MinION Equipment
Incubator
Centrifuge
Hood
MinION device
Reagents
DNA extraction
reagents
MinION reagents
Staff with
minimal
training for
samples
analysis
Highly trained
staff for data
analysis
<3days 25–50 - Reference
strain>
- High coverage
needed to improve
specificity
- Field laboratory for
sample analysis
- National reference
laboratory/Research
laboratory for data
analysis
[48–
50]
Q-POC Equipment
QPOC device
Reagents
QPOC cassettes
Reagents
Staff with
minimal
training
<30min TBD - Parasite DNA
sample with
known
genotype
- Sample
without DNA
template
- Point of care [51]
https://doi.org/10.1371/journal.pone.0204347.t001
TPP molecular assays for antimalarial resistance
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General characteristics
Intended use. The goal of a molecular assay is to detect genetic markers associated with
antimalarial drug resistance in P. falciparum parasites using blood samples from infected indi-
viduals. Discussions were held to assess whether Plasmodium vivax should also be included in
the TPP. The final consensus was that priority should be given to P. falciparum, as molecular
markers are well characterised for decreased susceptibility to artemisinins and resistance to
partner drugs for P. falciparum, but not for P. vivax. Rather, currently there is no clear evi-
dence of P. vivax resistance to artemisinins, and for P. vivax resistance to chloroquine (CQ),
amodiaquine (AQ) and sulfadoxine-pyrimethamine (SP), molecular markers have not been
validated [52].
Target population. The target population is any individual infected with P. falciparum.
Target users. The target users are highly trained laboratory technicians. There was a con-
sensus that surveillance of antimalarial drug resistance with current technologies would be
best conducted by national or regional reference laboratories that receive samples from senti-
nel sites or other national sources.
Implementation level. The target implementation level is regional or national reference
laboratories. Having reference laboratories performing all the analyses at a centralised facility
will probably be most cost-effective and provide the most accurate results. In addition, con-
straining the implementation level to reference laboratories simplifies reporting, data monitor-
ing, and procedure harmonization.
Table 2. Participants’ characteristics.
Number Percentage (%)
Affiliation
• Academic institutions 13 72.2
• Public Health Institutions /International Organizations 3 16.7
• Industry 2 11.1
Gender
• Female 7 38.9
Professional qualifications
• PhD 10 55.6
• MD & PhD 3 16.7
• MD 3 16.7
• MD & ScD 1 5.6
• ScD 1 5.6
Institutions’ countries
USA 5 25
France 4 20
Switzerland 3 15
UK 3 15
Austria 1 5
Denmark 1 5
Kenya 1 5
Netherlands 1 5
Thailand 1 5
Some participants have a double affiliation.
https://doi.org/10.1371/journal.pone.0204347.t002
TPP molecular assays for antimalarial resistance
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Technical and performance characteristics
The most important performance criteria were analytical sensitivity, analytical specificity, the spe-
cific molecular markers to be analysed, test sensitivity, and test specificity (Table 3). Because most
samples will come from cross-sectional surveys, the minimum sensitivity for parasitaemia detec-
tion was set at the same level as that being used to characterise symptomatic infections. The opti-
mal sensitivity was set to be equivalent to the most sensitive techniques currently used either for
molecular diagnosis of malaria or detection of molecular markers associated with antimalarial
drug resistance. The consensus about analytical specificity was that the method should be particu-
lar for P. falciparum. As above, it was agreed that molecular markers for P. vivax resistance are not
yet adequately validated. A list of validated P. falciparum molecular markers was suggested
(Table 3). The technique of choice should be able to analyse all relevant molecular markers associ-
ated with antimalarial drug resistance. The outcome of the test should be easy to read and interpret
(mutant or wild type for SNPs or number of gene copies for CNVs). Optimally, it should be possi-
ble to quantify the percentage of each genotype in samples with multiple infections. The sensitivity
and specificity of the testing was set to be at least 90% (ideally 95%) compared to Sanger sequenc-
ing. The repeatability and reproducibility of the technique were set at kappa>0.8 and>0.7,
respectively, for minimal conditions, and>0.9 and>0.8, respectively, for optimal conditions.
Technical and operational characteristics
The operational characteristics of the molecular assay are summarized in Table 4. The discus-
sions during the meeting were mainly on the assay format, assay throughput, and sample
Table 3. Performance characteristics based on the consensus by the meeting of experts.
Characteristic Minimal (M) Optimal (O) Comment Ref.
Analytical sensitivity Limit of detection (LOD)
at 200 parasites/μl
Limit of detection at 1 parasite/μl The optimal analytical sensitivity should be comparable to the
sensitivity of Next generation sequencing (NGS) and RT-PCR.
The minimal requirement should be the detection of parasites
in symptomatic patients
[53,54]
Analytical specificity Specific for P. falciparum Specific for P. falciparum P. falciparum should be prioritized [55,56]
Molecular markers Pfcrt codon 76
Pfmdr1 codons 86/1246
and CNV
Pfdhfr codons 50/51/59/
108/164
Pfdhps codons 436/437/
540/581
PfKelch-13 codons 446/
458/493/539/543/561/580
Plasmepsin 2/3 CNV
Cytbc1 codon 268
All relevant molecular markers
associated with antimalarial drug
resistance
P. falciparum only
Testing outcome Binary for SNPs/ number
of copies for CNVs
Binary for SNPs with quantification of
the different alleles, and number of
copies for CNVs
The outcome should be wild type” or “mutant” for each allele,
ideally with the concentration of each in mixed infections
[41,53]
Testing sensitivity > 90% as compared to bi-
directional Sanger
sequencing
> 95% as compared to bi-directional
Sanger sequencing
Sanger sequencing would be used as the gold standard [41,44]
Testing specificity > 90% as compared to bi-
directional Sanger
sequencing
> 95% as compared to bi-directional
Sanger sequencing
Same as for sensitivity. However, specificity should be given
priority over sensitivity
[41,44]
Repeatability (inter-
operators)
Kappa > 0.8 Kappa > 0.9 The technique should be reproducible between technicians.
Reproducibility
(inter-laboratories)
Kappa > 0.7 Kappa > 0.8 The technique should be reproducible between laboratories.
https://doi.org/10.1371/journal.pone.0204347.t003
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matrix. Concerning the assay format, there was consensus that a requirement for use of sophis-
ticated laboratory equipment was appropriate because analyses should be conducted by
national or regional reference laboratories. High throughput was preferred; however, it was
agreed that the assay should be flexible enough to allow the laboratory to analyse small quanti-
ties of samples when appropriate (i.e. no restriction by batch size). DBS was the preferred
Table 4. Operational characteristics based on the consensus by the meeting of experts.
Operational characteristics
Characteristic Minimal (M) Optimal (O) Comment Ref.
Assay format Lab based equipment at a reference
laboratory
Lab based equipment at a reference
laboratory
Assay throughput High throughput Automated high throughput Throughout should be flexible to allow testing
of low volumes of samples
Assay packaging Standard reagents Package of single kits with individual
reagents sharing user manual
The packaging should be developed for a high
throughput assay
Operation conditions 15˚C to 30˚C
[Up to 60% relative humidity (RH)]
15˚C to 35˚C [Up to 80% RH] The assay should be developed to work in a
reference laboratory in a malaria-endemic
country
Reagents
transportation and
storage stability
Cold chain Cold chain Cold chain is acceptable as the assay would be
developed for reference laboratories
In use stability 4 hours at 15˚C to 30˚C [Up to 60% RH] 4 hours at 15˚C to 35˚C [Up to 80% RH] Once reagents have been prepared, they should
be stable in a reference laboratory
Reagents
reconstitution
All reagents ready to use All reagents ready to use
Equipment Hoods/Thermocycler/ sequencer/
Computer/Gel electrophoresis unit/Gel
imaging system/Other equipment
Hoods/Thermocycler/ sequencer/
Computer/ Gel electrophoresis unit/Gel
imaging system/other equipment
For reference laboratories, different equipment
could be used
Power requirement Electric Electric The equipment needs to be at least electric
operated (M) or have a battery to be used in
places where power cuts could be frequent (O)
Maintenance Every 6 months Once a year Regular maintenance should be possible in
reference laboratories
Sample type Finger stick blood Finger stick blood
Sample matrix Dried blood spot (DBS) Used RDT DBS should be the default matrix for samples
collection, and ideally used RDT should be used
as source of DNA
Sample preparation  5 steps  3
Overall test
preparation
 10 steps, of which2 are timed  3 steps, of which1 are timed Same as above
Time to results 1 months 1 week From sample collection to results
Internal control Included Included Both negative and positive controls should be
included with all assays.
External control Available Included Both negative and positive controls should be
included with all assays.
Assay interpretation Unambiguous, recorded by operator Unambiguous, recorded by operator or
electronically
The interpretation of the results should be
simple
Data capture Manual by operator Electronic automated Data capture should be flexible and adaptable
Data transfer Manual by operator Automated via internet or Global System
for Mobile Communications (GSM)
connectivity
Same as above for data transfer
Training  1 week for technician with little
experience
 3 days for technician with little
experience
The technique should be easy to learn
Biosafety Moderate individual and low public
health risk
Low individual and public health risk According to risk-based classification of
diagnostics for WHO prequalification
[59]
https://doi.org/10.1371/journal.pone.0204347.t004
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format to collect samples. However, good quality filter paper should be used to ensure optimal
yield and quality of DNA, especially after long term storage [57]. Optimally, the assay should
be able to use DNA extracted from a positive rapid diagnostic test (RDT), as RDTs are cur-
rently widely used in malaria endemic countries, especially in Africa, offering at times the best
access to samples [58]. Importantly, assays should routinely include negative and positive con-
trols. It is of paramount importance that external controls are included for the assessment of
the assay and calibration, and that a good quality control and quality assurance system is
implemented to ensure good laboratory practice standardisation.
Assay cost characteristics
The cost of the assay should be low enough to be affordable in developing countries. The cost
to analyse one sample for all mutations should ideally not be more than 10 USD, comparable
to or cheaper than widely used PCR-RFLP assays [29].
Discussion
Molecular markers of antimalarial drug resistance have proved to be useful for detection of early
resistance emergence [5,7,60], spread of resistance [61], or absence of resistance [62], and are easy
to interpret [63]. Although TESs provide valuable resistance measurements that are easiest to
directly translate to policy, they are confounded by many factors, including clinical immunity and
varied pharmacokinetics, and they require extensive time for completion, so resistance may only
be apparent once parasites resistant to both components of a drug combination have spread
widely [64]. Molecular techniques have the advantage of providing information in real time about
the prevalence and ideally the frequency of resistant parasite strains circulating in the population
using easily collected DBS or RDT samples [42,58,65], and this information is not typically con-
founded by clinical immunity. Even though, the presence of resistant parasites does not necessar-
ily predict treatment failure [66], increasing prevalence of validated molecular markers of
antimalarial drug resistance is associated with increasing treatment failure, and thus molecular
markers offer a valuable early indicator of resistance emergence [67], and a practicable means of
determining thresholds for policy makers. As an example, the WHO policy on Intermittent pre-
ventive treatment for infants (IPTi) with SP recommends50% prevalence of Pfdhps 540 muta-
tion as the threshold for implementation of SP-IPTi [68]. A variety of different techniques to
assess molecular markers associated with antimalarial drug resistance are already available
(Table 1), however standardisation is needed to improve the quality of generated data [1].
New and improved technologies should focus on simple techniques that can be used by lab-
oratories in malaria endemic countries. Techniques should be highly sensitive to detect minor-
ity strains, but also highly specific to yield accurate results. Indeed, according to the consensus
obtained during the meeting of experts, priority should be given to specificity over sensitivity;
it is better to miss strains at low level than to give inaccurate prevalence data. Increased multi-
plicity of infection in high transmission settings may compromise assessment of antimalarial
drug resistance molecular markers [69]. Indeed, genotyping of samples with multiple infec-
tions is challenging, as it is difficult to link different mutations to a specific strain, and there-
fore accurately assess haplotypes or frequencies of specific strains, in particular when
considering CNV. New technologies under development, including amplicon sequencing,
may allow assessment of drug resistance variants among polygenomic infections [70–74].
However, in the setting of high multiplicity of infection, prevalence data remains useful for
surveillance purposes [75]. Determination of CNV is a minimal requirement in this TPP, as
resistance to some of the important artemisinin partner drugs such as mefloquine and pipera-
quine is associated with changes in gene copy numbers [76,77]. Currently, sequencing
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technologies and real-time PCR offer most of the desired characteristics described in the cur-
rent TPPs, including the determination of CNVs (Table 1), and those technologies are becom-
ing increasingly available and affordable in developing countries [1]. Other new techniques are
in development that could improve standardisation, with no DNA amplification [78,79] or
DNA extraction step requirement [51,80]. However, these techniques are still at an early stage
of development and are mainly under evaluation for diagnosis, and not surveillance.
Recent advances in sequencing technologies, such as next-generation sequencing (NGS)
platforms that enable rapid whole genome sequencing (WGS), can provide in-depth informa-
tion about molecular determinants of resistance, allowing detailed assessment of the spread of
resistant strains [81–83]. They can provide as well information about new emerging mutations
before they can be confirmed by phenotypic data from in vitro assessments and clinical data
when available. The main objective of a molecular-based surveillance system should be the
detection of resistance before it spreads. For artemisinin resistance, different foci have been
discovered, and molecular determinants other than pfKelch13 may be involved [84,85], requir-
ing a continuous search and validation for new molecular markers. The development of a sur-
veillance system included in the local health system could be envisioned; samples would be
collected at health posts, centres or hospitals and sent to reference laboratories for analysis and
validation, while clinical data could be shared through electronic-based information system
[86]. Combined with local epidemiological data; drug usage and treatment efficacy data, WGS
data could provide valuable information for modelling and predicting the spread of antimalar-
ial drug resistance [87]. The recent development of MinION nanopore portable sequencer and
its application to molecular markers of resistance could facilitate as well sample analysis at
point of care, while the data analysis could still be performed in the central reference labora-
tory [48,50]. NGS technologies also allow pooling of different samples by indexing them to
reduce the analysis costs [41,42]. Even though the costs of all these NGS technologies have dra-
matically reduced in recent years and are affordable for developing countries, they still require
high expertise in data analysis, and high computing power that are not always available in
those countries. However, the establishment of centres of excellence or regional reference labo-
ratories could overcome this issue.
To ensure the accuracy and the comparability of the results from different laboratories, a
good external quality assurance (EQA) system should be implemented, providing validated
and standardised external control material [88,89]. Indeed, different laboratories may use dif-
ferent protocols and standard operating procedures (SOPs) for the same methodology, and
there is variability in operating procedures in different laboratories. An analogous EQA
scheme for malaria nucleic acid amplification testing external quality assurance (NAAT EQA)
has been developed by WHO and FIND [90], and could potentially be expanded to molecular
markers of resistance.
Conclusion
In summary, techniques already exist with most of the required characteristics in this TPP for
assays to analyse molecular markers associated with antimalarial drug resistance, and could be
rapidly implemented in reference laboratories. Other techniques in development fulfil most of
the criteria specified by the TPP and could potentially improve data analysis standardisation.
However, the implementation of different techniques for routine surveillance of antimalarial
drug resistance would need a consensus from policy makers to define implementation proce-
dures, optimise their use, and implement good EQA practices. This TPP can also be used by
assay manufacturers to guide development of new technologies to facilitate efficient surveil-
lance of molecular markers associated with antimalarial drug resistance in endemic settings.
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